Drug Induced Scleroderma

Are you evaluating a patient for drug-induced scleroderma?

Yes

Does the patient have?

• sclerodermatous patches?

Yes

• poikiloderma?

Yes

• acral sclerosis?

Yes

• Raynaud's phenomenon?

Yes

• eosinophilia-myalgia?

Yes

• anti-nuclear antibody (ANA) positivity?

Yes

• other autoantibodies (anti-Scl-70, other)?

Yes

Is the patient exposed to?

• L-tryptophan?

Yes

• bleomycin?

Yes

• fosinopril?

Yes

• another drug?

Yes

Were clinical and/or laboratory findings present prior to exposure to the current medications?

Yes

Is there another diagnosis that can explain the findings better?

Yes

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Number of clinical and laboratory findings seen in drug-induced scleroderma

Has the patient been exposed to a drug implicated in causing drug-induced scleroderma?

Number of findings suggesting another diagnosis

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Seamlessly integrate our API library of over 5,000 evidence-based medical analytics into your products and workflows. Our APIs help you:

Build custom, automated clinical workflows tailored to your organization's needs.
Enhance your clinical decision support with advanced, evidence-based analytics.
Streamline revenue cycle management by integrating clinical analytics into billing, coding, and compliance processes.
Support payment and pre-approval processes with automated, standardized medical criteria.
Embed proven medical algorithms directly into your systems and services for consistent, high-quality outcomes.

With MedicalAlgorithms.com APIs, you can accelerate innovation, improve efficiency, and deliver more accurate, data-driven care—without reinventing the wheel.

Explore Medal API

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
- Scleroderma Risk Model for 5 Year Survival
Clinical Diagnosis, Including Family History For Genetics
- ARA Scleroderma Criteria Cooperative Study Preliminary Clinical Criteria for Systemic Sclerosis
Imaging Studies
Laboratory Tests
Other Testing
Criteria For Diagnosis
Severity, Prognosis, Stage
Differential Diagnosis And Mimics, Red Flags

Monitoring

Response To Therapy
Disease Progression
Comorbid Conditions
- Prognostic Factors for Patient with Juvenile Systemic Sclerosis
- Lung Severity Scale of Medsger for Patient with Systemic Sclerosis

Patient Concerns

End-of-life, Palliative Care
- Scleroderma Risk Model for 5 Year Survival

Evaluation

Results

Please fill out required fields.

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Monitoring

Patient Concerns

Specialty

Objective

ICD-10

Purpose: To evaluate a patient for clinical and laboratory findings associated with drug-induced scleroderma.

Evaluation

Results

Please fill out required fields.

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Monitoring

Patient Concerns

Specialty

Objective

ICD-10